The Blackstone Group, a major US private equity firm, has announced the acquisition of Takeda Consumer Healthcare Company (TCHC), a subsidiary of Takeda Pharmaceutical. Investment funds and other industries have been putting out feelers toward the pharmaceutical sector in recent…
TRENDS
Sales of Most Long-Listed Drugs Fall Short of Forecasts in Apr.-Sept.; Over 70% See Downward Revisions in Full-year Forecasts
Based on new drug makers’ settlements of accounts for April through September 2014, it is clear that companies are finding it more difficult to maintain earnings without launching new drugs and that global products are now driving earnings. This means…
To read the full story
TRENDS
- 51 Drugs Listed in 2019 with Total Peak Sales Forecast of 370 Billion Yen, Many for Orphan Diseases
December 27, 2019
- Top 10 PHARMA JAPAN Articles in 2019
December 26, 2019
- Sales per Drug Rep Hits Record High in FY2018 as Downsizing Speeds Up
August 30, 2019
- Chugai Running Offensive/Defensive Play towards EPS Growth Goal, Hemlibra Outpaces Target
August 9, 2019
- Japan SGLT2 Market Hits 70 Billion Yen as Combo Drugs Gain Ground
July 16, 2019
Measures focusing on risk management should be necessary to prevent disruptions in API supplies, Prof. Hiroyuki Sakamaki of Kanagawa University…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Despite the worldwide focus on inclusivity and diversity, it will take immediate action to counteract Japan’s growing gender gap. Study after study has proven that companies with more women in senior roles perform better financially, gaining a competitive edge from…